4.31
price up icon3.86%   0.16
after-market 시간 외 거래: 4.31
loading
전일 마감가:
$4.15
열려 있는:
$4.15
하루 거래량:
619.36K
Relative Volume:
1.08
시가총액:
$207.07M
수익:
$20.72M
순이익/손실:
$-100.84M
주가수익비율:
-1.6203
EPS:
-2.66
순현금흐름:
$-78.56M
1주 성능:
+5.64%
1개월 성능:
+14.93%
6개월 성능:
-26.07%
1년 성능:
-79.06%
1일 변동 폭
Value
$4.15
$4.40
1주일 범위
Value
$3.68
$4.40
52주 변동 폭
Value
$2.235
$28.93

4D몰큘러 테라퓨틱스 Stock (FDMT) Company Profile

Name
명칭
4 D Molecular Therapeutics Inc
Name
전화
(510) 505-2680
Name
주소
5858 HORTON STREET #455, EMERYVILLE
Name
직원
227
Name
트위터
Name
다음 수익 날짜
2024-12-13
Name
최신 SEC 제출 서류
Name
FDMT's Discussions on Twitter

FDMT을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
FDMT
4 D Molecular Therapeutics Inc
4.31 207.07M 20.72M -100.84M -78.56M -2.66
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
457.03 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.74 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
329.77 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
545.11 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
244.32 28.51B 3.81B -644.79M -669.77M -6.24

4D몰큘러 테라퓨틱스 Stock (FDMT) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-01-13 다운그레이드 BMO Capital Markets Outperform → Market Perform
2024-11-21 개시 Morgan Stanley Underweight
2024-09-23 다운그레이드 Cantor Fitzgerald Overweight → Neutral
2024-04-15 개시 Barclays Overweight
2024-02-07 재개 Goldman Buy
2023-10-26 개시 RBC Capital Mkts Outperform
2023-10-24 개시 Cantor Fitzgerald Overweight
2023-10-18 업그레이드 Leerink Partners Market Perform → Outperform
2023-07-05 개시 Chardan Capital Markets Buy
2023-01-30 개시 BMO Capital Markets Outperform
2022-11-18 개시 H.C. Wainwright Buy
2022-11-15 업그레이드 Goldman Neutral → Buy
2022-08-12 다운그레이드 SVB Leerink Outperform → Mkt Perform
2022-06-22 개시 Jefferies Buy
2022-01-04 개시 SVB Leerink Outperform
2021-01-05 개시 BofA Securities Buy
2021-01-05 개시 Evercore ISI Outperform
2021-01-05 개시 Goldman Neutral
모두보기

4D몰큘러 테라퓨틱스 주식(FDMT)의 최신 뉴스

pulisher
Jun 17, 2025

Cystic Fibrosis Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Globe and Mail

Jun 17, 2025
pulisher
Jun 17, 2025

Oligonucleotides Clinical Trial Pipeline Analysis Demonstrates 280+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight - SINA HONG KONG LIMITED

Jun 17, 2025
pulisher
Jun 16, 2025

Gene Therapy in Ophthalmology Market Set to Transform Vision Restoration Landscape by 2034 | Says DelveInsight - Barchart.com

Jun 16, 2025
pulisher
Jun 16, 2025

Harbor Capital Advisors Inc. Invests $99,000 in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World

Jun 16, 2025
pulisher
Jun 13, 2025

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Stock Position Raised by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World

Jun 13, 2025
pulisher
Jun 12, 2025

4D Molecular Therapeutics (NASDAQ:FDMT) Given “Sell (D-)” Rating at Weiss Ratings - Defense World

Jun 12, 2025
pulisher
Jun 12, 2025

908 Devices’ (MASS) “Sell (D-)” Rating Reiterated at Weiss Ratings - Defense World

Jun 12, 2025
pulisher
Jun 12, 2025

Organigram (TSE:OGI) Stock Price Up 2% – Should You Buy? - Defense World

Jun 12, 2025
pulisher
Jun 12, 2025

Analysts Issue Forecasts for FDMT FY2026 Earnings - Defense World

Jun 12, 2025
pulisher
Jun 11, 2025

Vivani Medical Appoints Anthony Baldor as Chief Financial Officer - The Manila Times

Jun 11, 2025
pulisher
Jun 11, 2025

Cantor Fitzgerald Forecasts UTHR FY2026 Earnings - Defense World

Jun 11, 2025
pulisher
Jun 11, 2025

Cantor Fitzgerald Forecasts UBER FY2026 Earnings - Defense World

Jun 11, 2025
pulisher
Jun 11, 2025

Cantor Fitzgerald Forecasts TYL FY2026 Earnings - Defense World

Jun 11, 2025
pulisher
Jun 11, 2025

Analysts Set Expectations for SHLS FY2026 Earnings - Defense World

Jun 11, 2025
pulisher
Jun 11, 2025

Equities Analysts Offer Predictions for VYGR FY2026 Earnings - Defense World

Jun 11, 2025
pulisher
Jun 11, 2025

Cantor Fitzgerald Predicts TG Therapeutics FY2026 Earnings - Defense World

Jun 11, 2025
pulisher
Jun 11, 2025

Analysts Set Expectations for SLNO FY2026 Earnings - Defense World

Jun 11, 2025
pulisher
Jun 11, 2025

Equities Analysts Offer Predictions for SPWR FY2026 Earnings - Defense World

Jun 11, 2025
pulisher
Jun 11, 2025

Brokers Set Expectations for XENE FY2026 Earnings - Defense World

Jun 11, 2025
pulisher
Jun 10, 2025

Fabry Disease Market to Grow Rapidly During the Study Period (2020–2034) | DelveInsight - GlobeNewswire

Jun 10, 2025
pulisher
Jun 05, 2025

4D Molecular Therapeutics Being Investigated on Behalf of 4D Molecular Therapeutics, Inc. Investors. Contact Levi & Korsinsky For Details - ACCESS Newswire

Jun 05, 2025
pulisher
Jun 04, 2025

4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates - MSN

Jun 04, 2025
pulisher
Jun 04, 2025

ProShare Advisors LLC Increases Position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World

Jun 04, 2025
pulisher
Jun 03, 2025

Bank of America Corp DE Buys 127,885 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World

Jun 03, 2025
pulisher
Jun 03, 2025

Two Sigma Investments LP Acquires 208,021 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World

Jun 03, 2025
pulisher
May 31, 2025

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World

May 31, 2025
pulisher
May 31, 2025

Tesco (LON:TSCO) Stock Crosses Above 200-Day Moving Average – Should You Sell? - Defense World

May 31, 2025
pulisher
May 31, 2025

Telsey Advisory Group Forecasts Macy’s’ Q2 Earnings (NYSE:M) - Defense World

May 31, 2025
pulisher
May 29, 2025

D. E. Shaw & Co. Inc. Purchases 12,217 Shares of Arcos Dorados Holdings Inc. (NYSE:ARCO) - Defense World

May 29, 2025
pulisher
May 29, 2025

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Stock Position Lowered by D. E. Shaw & Co. Inc. - Defense World

May 29, 2025
pulisher
May 28, 2025

4DMT to Participate in Upcoming Investor Conferences | FDMT Stock News - GuruFocus

May 28, 2025
pulisher
May 28, 2025

4DMT to Participate in Upcoming Investor Conferences - Eagle-Tribune

May 28, 2025
pulisher
May 27, 2025

4D Molecular Therapeutics (NASDAQ:FDMT) Receives Sell (E+) Rating from Weiss Ratings - Defense World

May 27, 2025
pulisher
May 27, 2025

Millennium Management LLC Acquires 1,337,497 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World

May 27, 2025
pulisher
May 26, 2025

4D Molecular Therapeutics’ SWOT analysis: gene therapy stock faces durability challenges amid pipeline progress - Investing.com

May 26, 2025
pulisher
May 25, 2025

Deutsche Bank AG Sells 560,784 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World

May 25, 2025
pulisher
May 25, 2025

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Shares Acquired by Northern Trust Corp - Defense World

May 25, 2025
pulisher
May 25, 2025

BNP Paribas Financial Markets Makes New Investment in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World

May 25, 2025
pulisher
May 21, 2025

Spotlight On 3 Penny Stocks With Market Caps Under $500M - Yahoo Finance

May 21, 2025
pulisher
May 21, 2025

Jane Street Group LLC Increases Stake in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World

May 21, 2025
pulisher
May 18, 2025

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Shares Sold by Price T Rowe Associates Inc. MD - Defense World

May 18, 2025
pulisher
May 17, 2025

Dimensional Fund Advisors LP Cuts Stock Position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World

May 17, 2025
pulisher
May 16, 2025

4DMT Boosts Talent Acquisition: 31,800 RSUs Granted as Biotech Firm Accelerates Growth - Stock Titan

May 16, 2025
pulisher
May 15, 2025

FY2025 EPS Estimates for FDMT Decreased by Cantor Fitzgerald - Defense World

May 15, 2025
pulisher
May 15, 2025

HC Wainwright Analysts Boost Earnings Estimates for FDMT - Defense World

May 15, 2025
pulisher
May 12, 2025

Chardan Adjusts Price Target on 4D Molecular Therapeutics to $25 From $28, Maintains Buy Rating - marketscreener.com

May 12, 2025
pulisher
May 12, 2025

Hsbc Holdings PLC Grows Stock Holdings in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World

May 12, 2025
pulisher
May 12, 2025

Barclays Cuts 4D Molecular Therapeutics (NASDAQ:FDMT) Price Target to $38.00 - Defense World

May 12, 2025
pulisher
May 12, 2025

Chardan Capital Cuts 4D Molecular Therapeutics (NASDAQ:FDMT) Price Target to $25.00 - Defense World

May 12, 2025
pulisher
May 12, 2025

The Goldman Sachs Group Cuts 4D Molecular Therapeutics (NASDAQ:FDMT) Price Target to $44.00 - Defense World

May 12, 2025
pulisher
May 11, 2025

Wells Fargo & Company MN Boosts Holdings in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World

May 11, 2025

4D몰큘러 테라퓨틱스 (FDMT) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading

4D몰큘러 테라퓨틱스 주식 (FDMT) 내부자 거래

내부자 거래 관계 날짜 거래 비용 #주식 가치 ($) #주식 총계
Bizily Scott
Chief Legal Officer
Sep 16 '24
Sale
16.33
500
8,165
6,781
Bizily Scott
Chief Legal Officer
Aug 19 '24
Option Exercise
6.49
500
3,245
7,281
Bizily Scott
Chief Legal Officer
Aug 19 '24
Sale
15.00
500
7,500
6,781
Bizily Scott
Chief Legal Officer
Jul 16 '24
Option Exercise
7.60
1,750
13,295
8,531
Bizily Scott
Chief Legal Officer
Jul 16 '24
Sale
27.11
1,750
47,442
6,781
Bizily Scott
Chief Legal Officer
Jul 11 '24
Option Exercise
15.78
1,996
31,497
8,777
Bizily Scott
Chief Legal Officer
Jul 11 '24
Sale
25.00
1,996
49,900
6,781
Kirn David
Chief Executive Officer
Jul 10 '24
Option Exercise
14.55
12,923
188,077
1,072,076
Kirn David
Chief Executive Officer
Jul 10 '24
Sale
22.49
12,923
290,598
1,059,153
Bizily Scott
Chief Legal Officer
Jul 01 '24
Option Exercise
7.55
4,248
32,089
5,985
$20.44
price down icon 1.45%
$36.19
price up icon 0.86%
$22.62
price up icon 6.70%
$98.24
price up icon 0.64%
$108.26
price up icon 0.70%
biotechnology ONC
$244.32
price down icon 0.34%
자본화:     |  볼륨(24시간):